Amidst the turbulent year, some important M&A deals were executed, including high-value exits that returned capital to investors. Head of European Strategic Relationships at Goodwin describes how clients have taken advantage of a robust market for traditional deal structures like IPOs and M&A, but also seeing another financial product, SPACs, become a key part of the tool-kit for the most ambitious UK biotechs. Read the UK BioIndustry Association article here.